InterMune lung drug passes trial, shares nearly triple – Reuters
MarketWatch (blog) |
InterMune lung drug passes trial, shares nearly triple
Reuters It is also approved in Japan, South Korea, China, India, Argentina and Mexico. IPF is an irreversible condition that leads to progressive loss of lung function due to scarring, which hinders a lung’s ability to absorb oxygen. InterMune said it expected … InterMune shares more than double on tests for lung-disease treatmentMarketWatch (blog) InterMune more than doubles on lung-drug studyMSN Money InterMune hits 2-year high on US Esbriet studyBusinessweek |
